IDIBELL Cancer Conference on Personalised Cancer Medicine
Del 3 al 4 de diciembre de 2012
Hotel Hesperia Tower, Barcelona
Hotel Hesperia Tower, Barcelona
|
03 de Diciembre de 2012 |
|
| 08.00-09.00 |
Registration |
| 09.00-09.15 |
Organizers Welcome |
| 09.15-10.00 |
Opening Lecture: Michael Karin (University of California, San Diego, USA) “Inflammation, metabolism, aging and cancer: Dangerous Liaisons.” |
| 10.00-14.30 |
The Role of Epigenetics and DNA repair 10.00-10.40: Manel Esteller (IDIBELL, Spain) “PharmacoEpigenetics: Genes and Drugs.” 10.40-11.20: Nick La Thangue (Oxford, UK) “HDAC inhibitors: from bench to clinic, and back again.” 11.20 - 12.00: Coffee break and poster session 12.00-12.40: Scott A. Armstrong (Dana Farber, USA) Title TBC 12.40-13.20: Christopher Vakoc (Cold Spring Harbor, USA) "Roles for bromodomain proteins and histone methyltransferases in the pathogenesis of cancer". 13.20-13:30: Selected short talk 2 13.30-14.30: Lunch and poster session |
| 14.30-16.50 |
The Role of Hypoxia and the Proteasome 14.30 - 15.30: Gregg Semenza (Johns Hopkins, USA) “Role of HIF-1 in Breast Cancer Metastasis.” 15.30 - 16.10: Stig Linder (Karolinska Institute, Sweden) “Inhibition of proteasome deubiquitinating activity as a novel cancer therapy.” 16.10 - 16.20. Selected short talk 2 16.20 - 16.50. Coffee break |
| 16.50-18.50 |
The Role of Metabolism and Cell Signaling I 16.50 - 17.30: George Thomas (IDIBELL, Spain) “Ribosome Biogenesis, Cell Cycle Checkpoints and Cancer Progression” 17.30 - 18.10: David Sabatini (Whitehead Institute, USA) “Growth Control by the mTOR Pathway.” 18.10 - 18.50: Brendan Manning (Harvard, USA) “The TSC-mTOR circuit links oncogenic signaling to cancer metabolism.” |
|
04 de Diciembre de 2012 |
|
| 09.00-14.40 |
The Role of Metabolism and Cell Signaling II 09.00 - 09.40: Tak Mak (Campbell Institute, Canada) Title TBC 09.40 - 10.20: Douglas Green (St. Jude Children’s Research Hospital, USA) “How caspases cause and prevent cell death.” 10.20 - 11.00: Guido Kroemer (INSERM, France) “How cancer cell metabolims impacts on anticancer immunosurveillance”. 11.00 - 11.30: Coffee break and poster session 11.30 - 12.10: Cristina Muñoz-Pinedo (IDIBELL, Spain) "Targeting metabolism to kill cancer cells." 12.10 - 12.40. Sara Kozma (IDIBELL, Spain) “mTOR inhibitors in hepatocellular carcinoma” 12.40 - 13.20. René Bernards (The Netherlands Cancer Institute, The Netherlands) “Using funcitonal genomics to identify mechanisms of response to cancer drugs”. 13.20 - 13.30: Selected short talk 3 13.30 - 14.40: Lunch and poster session |
| 14.40-18.20 |
The Impact on Clinical Translation 14.40 - 15.20: Rafael Rosell (ICO, Spain) “Additional actionable mutations in EGFR mutant non-small cell lung cancer”. 15.20 - 16.00: Josep Tabernero (Vall d’Hebron Hospital, Spain) “Genomic-based cancer treatment: prospects and challenges”. 16.00 - 16.10: Selected short talk 4 16.10 - 16.40: Coffee break and poster session 16.40 - 17.20: Ramón Salazar (ICO, Spain) “New molecular classifications, risk individualization in early stages and strategic innovations in advanced” 17.20 - 18.00: Manuel Hidalgo (CNIO, Spain) “Pancreatic Cancer: From Molecular Understanding to PersonalizeTreatment.” 18.00 - 18.40: Alberto Bardelli (Institute for Cancer Research and Treatment, Italy) “Personalized therapies for metastatic colorectal cancer.” |
| 18.20-19.00 |
Closing Lecture 18.20 - 19.00: Jonathan Knowles Instituto Roche Distinguished Speaker (EPFL, Switzerland) “Personalized Cancer Medicine - What is it, Why do we need it and how do we get there?" |
Organizado por:
